bucindolol

bucindolol

An investigational, nonselective beta-blocker with vasodilating properties that reached phase-III (BEST) trials, but was dropped from development thereafter.

bucindolol

Bextra Cardiology An investigational nonselective beta-blocker with vasodilating properties; removed from marketplace
Mentioned in ?
References in periodicals archive ?
Drug Profiles mentioned in this report are AT-300, BMS-394136, BMS-919373, bucindolol hydrochloride, budiodarone, edoxaban tosylate, F-373280, ISIS-CRPRx, NIP-151, NYK-1112, OMT-33, OPC-108459, ranolazine ER, Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation, Small Molecule to Block Kv1.
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure (BEST)' calismasinda genel olarak busindolol tedavisinin sistolik kalp yetersizligi hastalarinda yararli olmadigi gosterilmistir (40).
patent on methods of treating heart failure patients with bucindolol hydrochlorid--tradenamed Gencaro--based on genetic testing.
Researchers reported that heart-failure patients with a certain genetic profile responded well to bucindolol, a beta blocker that had fallen out of favor because it wasn't very effective in the average patient.
Three studies looked at propranolol, one study at sotalol, one study at atenolol, one study at bucindolol, and one study at atenolol, metoprolol, and pindolol.
37) For example, carve-dilol and bucindolol are nonselective beta blockers with intrinsic vasodilator activity.
In a DNA subanalysis of the Beta-Blocker Evaluation of Survival Trial (BEST), the [beta]-blocker bucindolol improved survival and decreased hospitalizations in heart failure (HF) patients with the adrenergic receptor variant known as Arg 389, compared with placebo.
Two studies published in 1999, however, showed that both enalapril and bucindolol significantly reduced the risk of death among white patients with heart failure but not among black patients.
But in a major trial, a fourth [beta]-blocker, bucindolol, was not effective.
A study sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and the Department of Veterans Affairs (VA) found that, overall, the betablocker bucindolol did not increase survival for moderate to severe heart failure.
patent on methods of treating heart failure patients with bucindolol hydrochloride "C" tradenamed Gencaro--based on genetic testing.
Long term betablocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind randomized study of bucindolol versus placebo.